Welcome to Nofinity

Summary: Risk Researcher Warns: Why Shareholders Are Walking Blindly into Ruin + Germany's State Failure

In this interview, risk researcher Prof. Dr. Werner Gleisner analyzes the current risks for investors and companies. He warns of a dangerous risk blindness among many investors who focus only on cheap valuation metrics (like P/E ratio) without considering actual corporate risks. For Germany, he paints a bleak picture: competitiveness is declining, bureaucracy is paralyzing, and the state is failing to implement necessary reforms.

Germany's Weakness and Systemic Risks

• The risk situation for German companies has worsened due to geopolitical power shifts and self-inflicted problems (e.g., low productivity, high energy costs).
• Germany is in a weak position because it has set wrong priorities for years (e.g., ESG goals over economic growth).
• The biggest crisis could be a chance for reforms, but political gridlock (firewalls, lack of majorities) prevents quick solutions.

Risk Management – The Big Gap

• Many companies fail to meet legal requirements (StaRUG 2021): They must identify, quantify, and aggregate risks (Monte Carlo simulation).
• Without risk aggregation, companies miss combination effects – this is a ticking time bomb for bankruptcies.
• Auditors often do not check this; therefore, shareholders are blind to internal risks.

Value Investing 4.0 – With a Quality Filter

• Classic value investing (low P/E) is risk-blind: It confuses undervalued companies with high-risk cases.
• Modern strategy: first estimate the probability of bankruptcy (e.g., using equity ratio and return on total capital), then only select robust companies with a cheap valuation.
• Studies show: Profitability (high return on equity) is a stable success factor.

AI as Opportunity and Threat

• AI can process huge amounts of data but is often used incorrectly for business questions (e.g., expected value vs. most likely value).
• Properly curated, AI helps with risk analysis and decision templates.
• Danger: AI amplifies human errors and does not replace decision-makers' responsibility.

Conclusion and Outlook

• Within the next 10 years, 1–2 severe crises are likely (economic, financial, or geopolitical crisis).
• Investors should diversify globally, favor robust companies, and check for risk aggregation in annual reports.
• Germany needs three immediate measures: faster defense capability, restoration of competitiveness (reduce bureaucracy, foster innovation), and a comprehensive national risk analysis.

Original title: Risikoforscher warnt: Darum laufen Aktionäre blind ins Verderben + Deutschlands Staatsversagen

Summary: Bitcoin Just PROVED It Doesn't Need Saylor

This video analyzes how the Bitcoin price rallied despite Strategy (formerly MicroStrategy) pausing its purchases and even selling, disproving the thesis that Bitcoin depends on Michael Saylor.

The Turning Point: Strategy Stops Buying and Starts Selling

• On June 22, Michael Saylor made his last purchase of 520 Bitcoin. This was followed by a five-week pause – the longest since 2020.
• Just six days later, Bitcoin bottomed below $59,000.
• Strategy sold 3,588 coins straight into the low.
• The largest corporate buyer in the market walked away – and Bitcoin still recovered.

Why Saylor Changed Strategy

• On June 29, Strategy announced a new "Digital Credit Capital Framework," marking a complete reversal:
  • USD Reserve Policy: A minimum cash floor covering 12 months of interest and dividend payments.
  • Bitcoin Monetization Program: Authorization to sell coins worth up to $1.25 billion.
  • Share Buybacks: $2 billion authorized for buybacks of its own preferred and common stock.
  • Dividend Hike: Increased to 12% annually for the STRC preferred stock.
• CFO Andrew Kang stated: "Bitcoin is capital" – an asset to be deployed based on return.

The End of the Accumulation Flywheel

• Strategy raised over $1 billion through equity issuance in July but bought zero Bitcoin.
• Instead, the funds went to the credit reserve and share buybacks – the opposite of its previous strategy.
• Cash reserves hit an all-time high of $3.75 billion.

Bitcoin Rallied Anyway: Who Bought?

• Bitcoin ETFs: After $4.5 billion in outflows in June, inflows returned in July ($981 million over seven days).
• Other Companies: Japan's Metaplanet bought 2,823 Bitcoin in the same week Strategy was selling.
• Long-Term Holders: Shifted from distribution to net accumulation – smaller and mid-sized wallets absorbed the ETF redemptions.
• Bitwise CIO Matt Hogan: "Strategy's era as the dominant buyer is likely over. Institutions are filling the gap."

The Changed Risk Framework

• The sell program is capped at $1.25 billion (approx. 2.5% of holdings) – only 17% used so far.
• The liquidity reserve now covers 24–28 months of obligations (previously 10 months).
• The MNAV (Multiple Net Asset Value) briefly fell below 1 but recovered to 1.03 – the market is re-rating the strategy positively.

Conclusion: Bitcoin is No Longer a One-Man Bet

• The thesis that Bitcoin depends on Saylor has been disproven: Strategy paused and sold, yet Bitcoin rose – carried by ETFs and long-term holders.
• The risk of a forced Strategy sell-off is now quantifiable and limited.
• The marginal buyer has shifted from a single company to a decentralized group of institutions and retail investors.

Caution: Several smaller companies liquidated their Bitcoin holdings to service debt. Analysts warn of a potential retest of the mid-$50,000s if ETF demand fades.

Introduction

This video analyzes Oracle stock from a value investor's perspective. The speaker discusses why the market is skeptical despite high growth figures and whether the stock is a worthwhile 'picks and shovels' play in the AI sector.

Analyst Opinions and Market Situation

• Most analysts rate Oracle as Strong Buy, but the speaker points out that analysts often follow the stock price and haven't yet adjusted their targets to market developments.
• The average analyst price target implies a 90% upside, which the speaker considers unrealistic.
• Bulls argue for AI cloud growth and 'picks and shovels', while bears point to high capital expenditures (Capex) and unclear return on investment (ROI).

Fundamentals

• Revenue growth is at 20%, with cloud infrastructure growing by 93% and CPU/GPU infrastructure by 119%.
• Remaining performance obligations (RPO) have surged to $648 billion, indicating future revenue.
• However, debt levels are also rising sharply, as Oracle finances investments through debt and preferred shares.

Criticism and Risks

• The speaker argues that growth could be circular, similar to hyperscalers, since many customers themselves are unprofitable.
• Oracle is betting that AI will remain in high demand, but no one knows whether chips and infrastructure will still be valuable by 2030.
• The stock has fallen about 60% from its peak, showing the market recognizes the risks.

Conclusion

• The speaker views Oracle as speculative gambling rather than a safe investment.
• He compares it to Bitcoin – a game one might play, but the outcome is unknown.
• For him, if uncertainty is too high and achieving financial goals isn't guaranteed, he skips the stock and invests elsewhere.

📉 Sentiment at Rock Bottom – Is Bitcoin Bottom In?

The host analyzes the current market sentiment after a week full of negative news:

• Sentiment in the toilet: Social media morale is extremely low. The saying "when the last optimist leaves the room" often marks a market bottom.
• Bitcoin price stable: Despite a barrage of bad news (Coldcard exploit, MicroStrategy sales, Iran tensions), Bitcoin holds in a tight range between $60k and $64k. There is hardly any selling pressure.

🔍 Secret Bull Signals Despite the FUD

• Whales accumulating: Large addresses have added hundreds of thousands of Bitcoin during the drawdown.
• Network activity: Active addresses spiked to a three-year high (~1 million), partly due to security moves after the Coldcard incident.
• Technical indicators: The adaptive sellside ratio shows a deep blue accumulation zone. The short-term holder realized price sits at $67k – a breakout above would be a strong bullish signal.
• Historical patterns: Data from 10x Research and K33 shows that periods of extreme low sentiment and high short-term holder losses have historically offered the best buying opportunities. Returns over the next 12 months ranged from 69% to 360%.

🏦 MicroStrategy (MSTR) and Macro

• MSTR recovering: The stock reclaimed its 200-day moving average and trades at ~$92 (from $73 a few weeks ago). Michael Saylor continues to buy back shares.
• U.S. debt: National debt is nearing $40 trillion, driving currency debasement and making scarce assets like Bitcoin attractive long-term.
• Bitcoin vs. M2 money supply: Bitcoin has never been cheaper relative to global M2.

📊 Poll Results (Audience Sentiment)

Sentiment	Percentage
Fully checked out	6%
On the fence	8%
Still believe but not buying	42%
Holding strong and accumulating	44%

The poll shows a surprisingly positive bias among viewers – despite the overall pessimism.

Conclusion: The host sees parallels to previous bear markets and believes the bottom is near. The combination of extremely low sentiment, stable prices, and quiet accumulation points to an imminent recovery.

The 5 Sexiest Moka Pots Ever Made

This video explores five extraordinary moka pots created by the Italian company Alessi in collaboration with visionary designers. Under Alberto Alessi's leadership, the company transformed everyday objects into art by recruiting architects and engineers instead of conventional product designers.

---

1. Richard Sapper – The 9090 (Engineer)

• Approach: Functional beauty through mechanics.
• Sapper, a German engineer, radically improved the classic moka pot: made of stainless steel, cylindrical, with a one-handed cap that avoids unscrewing the hot bottom chamber.
• Mechanics are deliberately left visible – aesthetics arise from function.

2. Aldo Rossi – Laconica & La Cupola (Architect)

• Approach: Architecture and memory in the kitchen.
• Laconica: Strictly geometric – sphere, cone, cylinder – looks like a tower, challenging the kitchen landscape.
• La Cupola: Topped with a dome, reminiscent of a building, symbolizing community. The long handle acts like a staircase – transforming the daily coffee ritual into something ceremonial.

3. Michele De Lucchi – La Pulcina (Rebel)

• Approach: Playful science.
• De Lucchi, a member of the Memphis Group, designed a pot with horizontal grooves intended to lower temperature at the end of brewing to reduce sputtering.
• The beak-like spout (hence the name 'little chick') allows precise pouring. Form follows both function and playfulness.

4. Mario Trimarchi – Ossidiana (Poet)

• Approach: Narrative and nature.
• Inspired by Sicily's volcanic landscape and the rock obsidian.
• The surface is divided into irregular facets that reflect light differently from every angle. The pot feels like a natural find, not an industrial product.
• The smooth handle contrasts with the rough, fractured body – a reminder of creation through pressure and heat.

---

Conclusion: Five Answers to 'What is Design?'

Each designer reinterpreted the moka pot:

• Sapper: Beauty through intelligent engineering.
• Rossi: A household object with architectural authority.
• De Lucchi: Science, joy, and provocation combined.
• Trimarchi: Metal as a carrier of landscape and memory.

These pieces are not mere coffee makers, but arguments for different design philosophies – engineering, architecture, rebellion, and poetry – all expressed through the same humble coffee maker.

Introduction: Mitochondrial Peptides (MOTS-c)

• MOTS-c is a small peptide (12–40 amino acids) encoded in the mitochondrial genome.
• It is synthesized as an independent protein, not a fragment of a larger one.
• Translation likely occurs in the cytosol (not in mitochondria), because the mitochondrial code would otherwise produce a stop codon.

Function and Mechanism

• MOTS-c acts as a stress communicator between mitochondria and the nucleus.
• It is released when cells are under stress (e.g., exercise, infection, nutrient deprivation).
• Primary role: metabolic reprogramming – especially regulation of lipid and cholesterol metabolism and insulin sensitivity.
• It influences protein homeostasis (e.g., in muscle during heat stress from exercise).
• MOTS-c also has antimicrobial properties (evolutionary origin from mitochondrial bacterial ancestors) and modulates the immune system (e.g., interferon pathway).

MOTS-c and Exercise

• Exercise (aerobic) increases MOTS-c in muscle and blood.
• MOTS-c alone has little effect on happy cells – it only works during persistent stress (chronic adaptation).
• In mice (human equivalent ~60–65 years old), a 2-week injection of MOTS-c made them outrun middle-aged mice – not by building muscle, but by improving stress resilience.

MOTS-c and Aging

• MOTS-c blood levels tend to decline with age, but the ability to mount a stress response also decreases.
• MOTS-c can act as an adaptation signal: In old mice, it slowed muscle loss (sarcopenia) and reduced body fat without increasing muscle mass.
• Chronic administration (e.g., 3×/week) improved physical performance (walking test).

Genetic Variant and Diabetes

• A single nucleotide variant in the mitochondrial genome (common in East Asians) alters MOTS-c and increases type 2 diabetes risk – especially in men.
• Regular exercise completely eliminates this risk, likely because it lowers the baseline stress level.

Clinical Perspective

• An engineered MOTS-c analog (company CohBar) reached Phase 1b (safety) with positive signals for fatty liver and obesity, but the company closed during the pandemic.
• Currently, a FDA hearing is considering whether to list MOTS-c on the 503A bulk substance list (allowing compounding pharmacies to produce it with a prescription).
• Caution: No regulatory approval exists; many users obtain MOTS-c from unverified sources (e.g., China).

Conclusion and Outlook

• MOTS-c is a master regulator of metabolic and immune stress adaptation – not a simple on/off switch for a single disease.
• It may be particularly useful for prevention and healthy aging (sarcopenia, obesity), but approval as an anti-aging intervention is complex.
• Dr. David Lee hopes to see MOTS-c enter regulated clinical use within 3–5 years.

---

Note: No imperial units appeared in the transcript; all measurements are already metric.